Corcept Therapeutics Incorporated reported unaudited revenue results for the fourth quarter and full year ended December 31, 2013. The company reported estimated net revenue of $4.1 million for the fourth quarter of 2013. Fourth quarter 2013 revenue up 56% over third quarter 2013 revenue

The company reported estimated net revenue of 10.4 million for the full year.

The company estimates 2014 net revenue will be between $24 and $28 million. The company anticipates Korlym 2014 revenue to grow to a range of $24 million to $28 million, up from $10.4 million in 2013.